Publish Date:
December 2015
Volume 1, Issue 4

JSHD

Journal of Structural Heart Disease

OFFICIAL JOURNAL OF THE PICS FOUNDATION

PICS Foundation

PEDIATRIC AND ADULT INTERVENTIONAL CARDIAC SYMPOSIUM

Sidra Medical and Research Center

Qatar Foundation

Published by
Science International Corp.
ISSN 2325-4637

Now accepting papers at http://structuralheartdisease.org

SAVE THE DATE

JAN. 16-19, 2017

LOEWS MIAMI BEACH HOTEL

MIAMI

WWW.PICSYMPOSIUM.COM

LIVE CASE DEMONSTRATIONS • ABSTRACT SESSIONS • "MY NIGHTMARE CASE IN THE CATH LAB" • HOT DEBATES • WORKSHOPS • SMALLER BREAKOUT SESSIONS •

Editorial Board

William E. Hellenbrand	Yale University (New Haven, CT)
James Hermiller	The Care Group (Indianapolis, IN)
Howard Herrmann	University of Pennsylvania (Philadelphia, PA)
David Holmes	Mayo Clinic (Rochester, MN)
Noa Holoshitz	Rush University Medical Center (Chicago, IL)
Ralf Holzer	Sidra Medical & Research Center (Doha, Qatar)
Eric Horlick	University of Toronto (Toronto, Canada)
Reda Ibrahim	Montreal Heart Institute (Montreal, Canada)
Michel Ilbawi	Rush University Medical Center (Chicago, IL)
Frank Ing	LA Children's Hospital (Los Angeles, CA)
Alexander Javois	Hope Children's Hospital (Oak Lawn, IL)
Thomas Jones	Seattle Children's Hospital (Seattle, WA)
Saibal Kar	Cedars Sinai Medical Center (Los Angeles, CA)
Clifford Kavinsky	Rush University Medical Center (Chicago, IL)
Joseph Kay	University of Colorado (Denver, CO)
Damien Kenny	Rush University Medical Center (Chicago, IL)
Morton Kern	University of California Irvine (Irvine, CA)
Michael Kim	University of Colorado (Aurora, CO)
Seong-Ho Kim	Cheju Halla General Hospital (South Korea)
Susheel Kodali	Columbia University Medical Center (New York, NY)
Jackie Kreutzer	Pittsburgh Children's Hospital (Pittsburgh, PA)
Shelby Kutty	Children's Hospital and University of Nebraska Medical Center (Omaha, NB)
Bray Patrick-Lake	PFO Research Foundation (Boulder, CO)
Michael Landzberg	Boston Children's Hospital (Boston, MA)
Geoffrey Lane	Royal Melbourne Hospital (Melbourne, Australia)
Roberto Lang	University of Chicago Medical Center (Chicago, IL)
John Lasala	Barnes Jewish Hospital, Washington University (St. Louis, MO)
Martin B. Leon	Columbia University (New York, NY)
Daniel Levi	UCLA Medical Center (Los Angeles, CA)
Scott Lim	University of Virginia Health System (Charlottesville, VA)
Michael Mack	Baylor Healthcare System (Plano, TX)
Francesco Maisano	University of Zurich (Zurich, Switzerland)
Raj Makkar	Cedars Sinai Medical Center (Los Angeles, CA)
Robert March	Rush University Medical Center (Chicago, IL)
Gwen Mayes	VP National Patient Advocate Foundation (Washington, DC)
Pat McCarthy	Northwestern Memorial Hospital (Chicago, IL)
Doff McElhinney	New York University (New York, NY)
John Messenger	University of Colorado (Denver, CO)
Friedrich Mohr	Herzzentrum Universitaet Leipzig (Leipzig, Germany)
Tarek Momenah	Prince Salman Cardiac Center (Riyadh, Saudi Arabia)
Issam Moussa	(Jacksonville, FL)
Michael Mullen	The Heart Hospital (London, England)
David Muller	St. Vincent's Hospital (Sydney, Australia)
William O'Neill	Henry Ford Hospital (Detroit, MI)
Igor Palacios	Mass General Hospital (Boston, MA)
SJ Park	University of Ulsan College of Medicine (Seoul, Korea)
Carlos Pedra	Danta Pazzanese Instituto de Cardiologia (Sao Paolo, Brazil)
Alejandro Peirone	Children's Hospital of Cordoba (Cordoba, Argentina)
Giacomo Pongiglione	Bambino Gesu Hospital (Rome, Italy)
Matthew Price	Scripps Clinic (La Jolla, CA)
Robert Quaife	University of Colorado (Denver, CO)
Shakeel Qureshi	Evelina Children's Hospital (London, UK)

Steve Ramee	Oschner Clinic (New Orleans, LA)
Mark Reisman	Swedish Medical Center (Seattle, WA)
John Rhodes	Miami Children's Hopsital (Miami, FL)
Charanjit Rihal	Mayo Clinic (Rochester, MN)
Richard Ringel	Johns Hopkins Medical Center (Baltimore, MD)
Carlos Ruiz	Lenox Hill Hospital (New York, NY)
Ernesto Salcedo	University of Colorado (Denver, CO)
Joachim Schofer	Hamburg University Cardiovascular Center (Hamburg, Germany)
Paul Sorajja	Minneapolis Heart Institute Foundation (Minneapolis, MN)
Christian Spies	Queen's Heart Physician Practice (Honolulu, HI)
Frank Silvestry	University of Pennsylvania Hospital (Philadelphia, PA)
Gregg Stone	Columbia University (New York, NY)
Corrado Tamborino	University of Catania (Catania, Italy)
Vinod Thourani	Emory University (Atlanta, GA)
Jonathan Tobis	UCLA Medical Center (Los Angeles, CA)
Murat Tuczu	Cleveland Clinic Foundation (Cleveland, OH)
Zoltan Turi	Robert Wood Johnson Medical School (Camden, NJ)
Alec Vahanian	Bichat University Hospital (Paris, France)
Joseph J. Vettukattil	Spectrum Health (Grand Rapids, MI)
Kevin Walsh	Our Lady's Hospital (Dublin, Ireland)
John Webb	St. Paul Hospital Vancouver (British Columbia, Canada)
Brian Whisenant	Intermountain Medical Center (Salt Lake City, Utah)
Matthew Williams	Mount Sinai Medical Center (New York, NY)
Neil Wilson	University of Colorado (Denver, CO)
Evan Zahn	Cedars Sinai Medical Center (Los Angeles, CA)

JSHD
Journal of Structural Heart Disease

Volume 1, Issue 4, December 2015

Meeting Abstracts

Journal of Structural Heart Disease (ISSN 2325-4637) is an online open-access journal issued bi-monthly (6 issues per year, one volume per year) by Science International Corporation.

All correspondence should be directed to: Ziyad M. Hijazi, MD, Co-Editor-in-Chief, Journal of Structural Heart Disease, PO Box 26999, Doha, Qatar. Tel.: +974-4404-2116, Fax: +974-44041779, E-Mail: jshd@scienceinternational.org

JSHD
Journal of Structural Heart Disease

Meeting Abstracts

Journal of Structural Heart Disease, December 2015, Volume 1, Issue 4: 152-154
DOI: http://dx.doi.org/10.12945/j.jshd.2015.900-15

Published online: December 2015

CSI Africa 2015 Abstracts

Catheter Interventions in Congenital, Structural and Valvar Heart Disease

http://www.csi-congress.org/africa

USING AMPLATZER OCCLUDERS (ASO, VSD) FOR CLOSING NON-ATRIAL AND NON-VENTRICULAR SEPTAL DEFECTS

Abdurashid Mussayev[1], Serik Alimbaev[1], Saule Kadirova[2], Marat Aripov[1] Pya Yuriy Vladimirovich[1], Abikeeva Lazzat Sagadatovna[1]

[1] National Research Cardiac Surgery Center; Interventional; Cardiology,

[2] Jsc "National Scientific Center of Cardiac Surgery"; Cardiac Surgery; Interventional

Background: Interventions in a large variety of congenital heart defects may require improvisation. In our cases, we used a variety of devices for off-label purposes.

Objective: To study possibility of using Amplatzer Occluders (ASO, VSD) for closing non atrial and ventricular septal defects in 2 patients with CHD and 1 patient after knife injury.

Methods: The first patient, 11 years old, had an aorto-pulmonary window (APW). Diameter of APW was 8mm, and there was LAA 2015

pulmonary hypertension. The second patient had a communication between right pulmonary artery (PA) and left atrium. The non- invasive saturation was 74% and the mean pressure in PA was 7mm Hg. The third patient, 23 years old, had post-traumatic aneurysm of suprarenal part of abdominal aorta. The ostium of aneurysm was 7mm.

Results: In the first case, APW was closed by Amplatzer Septal Occluder (ASO) of 10mm diameter. There was minimal shunt through the occluder. After 1 month, there was no shunt. In the second case, communication was closed with Amplatzer VSD 10mm device. Saturation after closing the communication was 97% and the mean pressure in PA was 9mm Hg. In the third case, ostium of aneurysm was closed with a 10mm ASO.

TRANS-CORONARY ABLATION OF SEPTAL HYPERTROPHY (TASH) IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY (HOCM): ACUTE AND LONG-TERM SAFETY AND EFFICACY OUT-COME FROM A SINGLE CENTER EXPERIENCE

Afrah Haroon[1], Alfazir Omer[2], Rosli Ali[2]

[1] National Cardiothoracic Centre-Alshab Teaching Hospital; Interventional; Adult Cardiology; Khartoum, Sudan

[2] National Heart Institute; Interventional; Adult Cardiology; Kuala Lumpur, Malaysia,

Background: Trans-coronary ablation of septal hypertrophy (TASH) has been shown to reduce outflow obstruction and symptom relief in the short and intermediate period.

Objectives: The aim is to assess the long-term efficacy and safety of TASH in a single center experience.

Method: 33 patients were analyzed with symptomatic HOCM, who underwent TASH procedure between 2005- 2014. Procedural success was defined as improvement in patient symptoms and reduction of the left ventricular (LV) outflow tract pressure gradient by ≥ 50% on echocardiography.

Result: The mean age was 49.4 ± 11.4 years. The mean duration of follow-up was 3.6 ± 2.4 years. The number of septal branches ablated was one in 66.7%, and mean alcohol volume was 3.1 ± 1.8 ml. LVOT gradient reduction was achieved in 91% of patients immediately, with mean gradient reduction from 83 ± 37 mmHg to 42 ± 34mmHg. Most patients, (81.8%) showed clinical improvement in New York Heart Association class. 11 patients developed transient complete heart block and permanent pacemaker was required in one. There was significant improvement in severity of mitral regurgitation and inter-ventricular septum thickness with preserved LV function. All p value <0.05.

Conclusion: TASH is a safe and effective procedure in achieving immediate and significant long-term reduction in LVOT pressure gradient in symptomatic patient, as well as echocardiographic variables.

Fax +1 203 785 3346
E-Mail: jshd@scienceinternational.org
http://structuralheartdisease.org/

Published by Science International Corp.
ISSN 2326-4004

Accessible online at:
http://structuralheartdisease.org/

SURGICAL MANAGEMENT OF TRICUSPID ENDOCARDITIS IN DRUG ABUSERS: 10 CASES

Ben Youssef Atef[1], Zairi Sarra[2], Ghariani Zied[2], Bousnina Mouna[2], Gaied Dorsaf[2], Ouerghi Sonia[2], Kilani Tarek[2]

[1] Department of Cardiothoracic and Vascular Surgery, Al Ahli Hospital, Doha, Qatar

[2] Department of Thoracic and Cardio-vascular Surgery, Abderrahmen Mami Hospital, Ariana, Tunisia

Background: Tricuspid valve endocarditis is a common disease and represents 5 to 10% of cases of infective endocarditis. Invasive procedures and intravenous drug abuse are the main causes. In recent years, we have noticed an increase in the number of patients managed for severe tricuspid valve endocarditis secondary to intravenous drug abuse.

Objective: To assess the management of tricuspid valve endocarditis secondary to intravenous drug abuse, in a surgical department.

Methods: We report 10 cases of tricuspid valve endocarditis in intravenous drug-abuse patients, managed from January 2009 to December 2013 in the Department of Thoracic and Cardiovascular Surgery in Abderrahmen Mami Hospital Ariana, Tunisia.

Results: The mean age of the patients was 31.24 years. Valve replacement with a bioprosthesis was performed in 7 cases and vegetation removal with tricuspid valvoplasty in 3 cases. The postoperative course was uneventful in 9 cases. During follow-up, re- current bioprosthetic valve endocarditis and complete atrio-ventricular block occurred in 1 patient, requiring pacemaker implantation. One patient died with septic shock secondary to aspiration pneumonia.

Conclusion: Tricuspid valve endocarditis is an underestimated pathology and is often worsened by immune suppression. These patients should be systematically included in a postoperative rehabilitation program, in order to prevent recurrence.

TRANSCATHETER CLOSURE OF PATENT DUCTUS ARTERIOSUS WITH THE AMPLATZER DUCT OCCLUDER IN SUB-SAHARAN AFRICA

Jean Claude Ambassa[1], Kongnyuy Alfred[1], Jacques Cabral Tantchou[1], Mve Charles Mvondo[1], Gianfranco Butera[2], Alessandro Giamberti[2]

[1] St. Elizabeth Catholic General Hospital Shisong Cardiac Centre, Cameroon

[2] Department of Pediatric Cariology and Cardiac Surgery, San Donato, Italy

Background: During an 8 year period, a Cardiac Centre has been designed and developed in Sub-Saharan Africa. Three partners have worked towards the realization of this project: two Italian charities (Associazione Bambini Cardiopatici nel mondo and Cuore Fratello) and a local general hospital run by the Tertiary Franciscan Sisters of Bressanone. Two cardiologists, one anaesthesiologist, one cardiac surgeon and 18 nurses have been trained. A fully equipped centre for cardiac care (2 operating theatres, 12 ICU beds, one flat panel Siemens catheterization laboratory, 38 beds in the ward, 6 neonatal beds and two outpatient clinics) have been developed by this Euro-African collaboration.

Objective: The aim of this study was to analyse the safety and efficacy of percutaneous closure of patent ductus arteriosus (PDA) in symptomatic pediatric and adult patients in a Sub-Saharan African centre.

Methods: We conducted a retrospective study on 40 patients with clinically significant PDA. 29 were children aged between 2 and 17 years and 11 were adults aged between18 and 29 years. The procedure was carried out under deep sedation or general anesthesia with fluoroscopic control. The Amplatzer Duct Occluder (ADO I) and Muscular ventricular septal defect devices were used. Physical examinations, 12 lead ECG, echocardiogram, and chest X-ray were performed prior to the procedure.

Results: In 2 patients, there were restrictive PDAs, whilst 17 patients had moderate PDAs with increased pulmonary flow and 21 patients had large PDAs. Pulmonary arterial pressures in these patients were between 75 and 100% of the systemic pressure, and 3 patients had Eisenmenger syndrome. Two patients had complications with device embolization, in one of whom the device was retrieved and was successfully closed with a muscular VSD device. In 1 patient, the embolised device needed surgical retrieval. In all patients, the ADO I and muscular ventricular septal defect were used. No problems occurred during long term follow-up.

Conclusion: Successful and safe percutaneous treatment of PDA can be performed in a centre in Sub-Saharan Africa. Collaboration between developed countries and local developing institutions is mandatory to succeed and have long lasting results.

RAPID, RELIABLE RESOLUTION OF DUCTAL SPASM DURING PERCUTANEOUS DEVICE OCCLUSION OF PATENT DUCTUS ARTERIOSUS BY A NOVEL PROTOCOL

Rik De Decker[1], Jenny Thomas[2], Elmarie van der Merwe[3], John Lawrenson[4]

[1] Red Cross Children's Hospital; Interventional and General; Child Cardiology

[2] Red Cross War Memorial Children's Hospital; Anaesthetist; Child Anaesthesia

[3] Red Cross War Memorial Children's Hospital; Surgery; Child Surgery

[4] Tygerberg Children's Hospital/Red Cross Children's Hospital; Interventional; Pediatric Cardiology

Background: Ductal spasm is a rare, but important complication of device occlusion of patent ductus arteriosus (PDA). We describe a novel protocol that rapidly and completely reversed the spasm in 8 ex-preterm infants, who had ductal spasm during cath- eterizations for PDA occlusion.

Object and Purpose: Our objective was to develop a protocol for the recognition and safe management of ductal spasm during percutaneous PDA occlusion.

Methods: Eight infants born with gestational ages between 25 and 34 weeks presented for transcatheter PDA occlusion between 13 and 67 months of age. All 8 had ductal spasm immediately before, during or soon after induction of anaesthesia, or only after entering the PDA with a catheter. After detection of the spasm, the anaesthetist, in each case: 1) changed the mode of anaesthesia from inhaled sevoflurane

to total intravenous anaesthesia (TIVA) with propofol, 2) reduced the inhaled oxygen fraction to 21%, and 3) initiated a continuous intravenous infusion of Prostaglandin E1 (PGE1).

Results: Complete relaxation was attained after intravenous Prostaglandin E1 infusions of only 10-15 minutes duration. Whilst maintaining this protocol, 6 PDAs were successfully occluded.

Conclusion: Ductal spasm during transcatheter occlusion may be reliably resolved and the procedure safely completed by this simple protocol.

TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT PRESERVES RIGHT VENTRICULAR FUNCTION

Shaimaa A. Mostafa (MD)1, Abdrabu Abdelhakim (msc)2, Tarek H. Aboelazm (MD)1, Osama S. Arafa (MD)[1], Ahmed M. Elemam(MD)[2]

[1]Benha Faculty of Medicine, Egypt
[2] National Heart Institute, Egypt

Aim: To investigate the intermediate and short-term effects of transcatheter secundum atrial septal defect (ASD) closure on cardiac remodeling in children and adult patients.

Methods: 50 patients with secundum ASD, referred for possible transcatheter device closure, were subjected to history taking, physical examination, electrocardiographic assessment and transthoracic echocardiographic examination and were evaluated before the ASD closure, and 1 day, 3 months and 6 months after closure.

Results: At the 6 months follow up, electrocardiographic parameters of remodeling improved, and P dispersion decreased from 49.73 ± 9.01 ms to 30.53 ± 5.08 ms (p = 0.004), QT dispersion decreased from 67.6 ± 5.31 ms to 51.13 ± 5.73 ms (p = 0.003), QRS duration decreased from 134.4 ± 4.97 ms to 116.20 ± 3.47 ms (P = 0.002) , PR interval decreased from 188.87 ± 6.06 ms to 168.00 ± 6.16 ms (P = 0.002). At follow-up of 6 months, RVEDD had decreased from 25.67 ± 5.50 mm to 17.80 ± 2.7 mm (p = 0.001), and the LVEDD had increased from 33.17 ± 6.44 mm to 37.53 ± 5.15 mm (p = 0.002), Mean PAP decreased from 16.97 ± 3.37 mm Hg to 9.22 ± 1.37 mmHg (P = 0.000), RVSP decreased from 30.77 ± 4.69 mmHg to 18.8 ± 2.11 mmHg. After 6 months, 93.3% of the patients had normal RV size.

Conclusion: Transcatheter ASD device closure leads to significant improvement in right sided chamber dimension and function and can reverse electrical and mechanical changes in atrial and ventricular myocardium in children and adults in short and intermedi- ate term follow up.

JSHD
Journal of Structural Heart Disease

Meeting Abstracts

Journal of Structural Heart Disease, December 2015, Volume 1, Issue 4: 155-159
DOI: http://dx.doi.org/10.12945/j.jshd.2015.901-15

Published online: December 2015

LAA 2015 Abstracts

How to Close the Left Atrial Appendage

http://www.csi-congress.org/laa

LATVIAN LAA CLOSURE REGISTRY FIVE YEARS OF EXPERIENCE IN HIGH-RISK PATIENTS

Dr. Baiba Lurina[1], MD Ainars Rudzitis[2], Milda Usane[3], Anete Urke[3], Mara Katkovska[3], Dr. Gunita Lauva[4], Prof. Andrejs Erglis[5]

[1] Latvian Centre of Cardiology / Pauls Stradins Clinical University Hospital / Riga Stradins University, Riga, Latvia; Interventional; Adult Cardiology, Riga, Latvia

[2] Latvian Centre of Cardiology / Pauls Stradins Clinical University Hospital; Adult Cardiology; Interventional, Kekava, Latvia

[3] University of Latvia, Riga, Latvia; Interventional; Adult Cardiology, Riga, Latvia

[4] NHS Grampian, Aberdeen, United Kingdom of Great Britain and Northern Ireland; Interventional; Adult Cardiology, Aberdeen, United Kingdom

[5] Latvian Centre of Cardiology / Pauls Stradins Clinical University Hospital / University of Latvia, Riga, Latvia; Interventional; Adult Cardiology, Riga, Latvia

Background: Left atrial appendage (LAA) closure with the Watchman device and AMPLATZER Cardiac Plug (ACP) has been shown to be a safe and effective alternative to oral anticoagulant therapy. In real-world practice in Latvia, LAA closure is preformed in AF patients with high stroke and bleeding risk, distinction from the two randomized controlled trial of device closure for patients with atrial fibrillation. LAA 2015

Objectives: The purpose of the Latvian LAA clo prevention in high-risk patients with atrial fibrillation (AF).

Methods: This is a single centre prospective non-randomized longitudinal cohort study of LAA closure with the Watchman device and ACP during five years. The registry collected data about clinical condition, efficacy and safety events (ischemic/hemorrhagic stroke, death, systemic embolism, device thrombosis or embolization, pericardial tamponade) from May 2010 to September 2015.

Results: In total 29 LAA closure cases were studied. Successful LAA closure was achieved in 96.6% of cases (n=28). The Watchman device was implanted in 50% and the ACP in 50% of cases. Mean CHA2DS2-VASc score was 6.3 (1.6) and HAS-BLED score - 3.3 (1.0). The main indication for closure was recurrent ischemic stroke and low compliance with warfarin usage. Serious peri-procedural safety events (device embolization of a Watchman device) occurred in one patient (n=1). Mean follow-up time was 38 (19.8) months, patients followed n=26. During 45 post-procedural days there was one (n=1) device thrombosis without clinical sequelae. After day 45, ischemic stroke occurred in 2 patients (2.3 per 100 patient-years) and non-cardiovascular death (from liver cancer) in one patient (1.2 per 100 patient-years).

Conclusions: LAA closure is a safe and effective method for thromboembolic stroke prevention in patients with atrial fibrillation and high risk of stroke and bleeding.

CROSS-SECTIONAL COMPUTED TOMOGRAPHIC SUPERIOR TO 2D AND 3D TEE FOR LAA CHARACTERIZATION OF SIZE AND THEREFORE DEVICE SELECTION

Dee Dee Wang, Marvin Eng, Sachin Parikh, Mehnaz Rahman, Mohammad Zaidan, Adam Greenbaum, William O'Neill

Henry Ford Hospital, Detroit, Michigan, USA

Background: Standardized LAA sizing is based on 2D transesophageal (TEE) measurements of the left atrial appendage (LAA). However, 3DTEE and CT have proven superior to 2DTEE for multiple structural interventional procedures.

Objective: The aim of this study is to evaluate LAA ostium width and length by 2DTEE, 3DTEE, and CT to determine the optimal imaging modality for accurate device selection.

Methods: From May through August 2015, 22 patients underwent LAA occlusion with WATCHMANTM. All patients received pre- procedural CT scan, and intraprocedural 2D and 3D TEE. Maximal width and length of LAA were obtained at 0, 45, 90, 135 degrees by 2D /3DTEE. Paired t-tests were applied to look for differences between CT sizing and each TEE methodology. Bland-altman plots were applied to compare each TEE type to CT.

Results: 22 patients underwent successful implantation of the WATCHMANTM device with CT guided sizing. CT maximal LAA width was larger than 2DTEE (p<0.001) and 3DTEE (p=0.002). CT maximal

Fax +1 203 785 3346
E-Mail: jshd@scienceinternational.org
http://structuralheartdisease.org/

Published by Science International Corp.
ISSN 2326-4004

Accessible online at:
http://structuralheartdisease.org/

LAA length was longer in 21 of 22 patients versus 2D TEE (p<0.001). There were no LAA ruptures. Each patient required only 1 device size. There were 3 peri-watchman leaks (< 5mm) secondary to accessory LAA pedunculation and not device sizing. 2D TEE maximal width would have required bigger device in 9 / 22(40.9%) patients. 3DTEE maximal width would have required bigger device in 7 / 22(31.8%). 2D TEE length would have excluded 5 patients from LAA occlusion.

Conclusion: CT guided LAA sizing is superior to 2D and 3DTEE assessment.

DELIVERABILITY, CONFORMABILITY, AND HEALING RESPONSE OF WATCHMAN FLX LAAC DEVICE

Elena Ladich[1] Dongming Hou[2], Brian Tischler[2], Alex Pflugfelder [2], Barbara Huibregtse[2], Renu Virmani[1]
CVPath[1] & BSC[2] , USA

Background: WATCHMAN FLX (WM-FLX) is the next generation WATCHMAN (WM) device.

Objective: The aim of this study is to compare WM-FLX and WM for implant deliverability, LAA conformability, and for biologic healing response at 45 and 90 days in the canine model.

Methods: LAA ostium was measured under TEE to determine device sizing. WM-FLX devices were implanted in 12 canines to evaluate the healing response. Half were terminated at 45d and half at 90d, respectively.

Results: 100% of WM-FLX canines (6/6) and 75% of WM canines (6/8) were successfully deployed (one excluded due to pericardial effusion, one for unfavorable LAA). The WM-FLX cohort required fewer partial and full recaptures. WM-FLX had no observed peri- device jets. (Table 1).

Table 1: Deliverability and Conformability Comparison

	WM	WM-FLX
Total devices/dogs used	10/6	6/6
Full recaptures	4	2
Partial recaptures	3	2
Dogs with Peri-device jet (<2mm)	2	0

WM-FLX showed a similar biologic healing response when compared to WM at both 45d and 90d. Endocardial tissue growth was complete to near-complete in all devices with the exception of single canine from the WM group at 90d in which there was minimal thrombus associated with slight protrusion of the device into the left atrium. Inflammation was minimal in all devices.

Conclusion: WM-FLX showed an improvement in both deliverability and LAA conformability, and had a similar healing response compared to WM.

RATIONALE OF CEREBRAL PROTECTION DEVICES IN LEFT ATRIAL APPENDAGE OCCLUSION

Felix Meincke[1], Felix Kreidel[1], Tobias Spangenberg[1], Christian Frerker[1], Oscar Sanchez[2], Elena Ladich[2], Karl-Heinz Kuck[1], Alexander Ghanem[1]
[1] Asklepios Klinik St. Georg, Abteilung für Kardiologie, Hamburg, Germany
[2] CV Path Institute Inc., Gaithersburg, USA

Background: Periprocedural stroke has been reported after interventional left atrial appendage occlusion (iLAAO). In transcatheter aortic valve replacement (TAVR), the use of a cerebral protection device has been shown to reduce cerebral lesions assessed with magnetic resonance imaging. Our aim was to assess the feasibility of cerebral protection devices in iLAAO and to analyze the amount and type of debris captured.

Methods: In five consecutive patients undergoing iLAAO, the Sentinel CPS® cerebral protection device was used. For iLAAO, the Watchman® device was used in two patients and the Amulet® in three. After iLAAO, the filters underwent histopathological examination.

Results: A total of 10 filters (one proximal and one distal filter for each patient) were collected and underwent histopathological analysis (CV Path Institute Inc.). Debris was found in all patients (9/10 filters). Acute thrombus was found in 3 patients (2 Watchman®; 1 Amulet®), organizing thrombus in 4 patients (1 Watchman®; 3 Amulet®). Two Amulet® patients had endocardial or myocardial tissue in their filters. None of the filters included calcifications or other foreign material. The maximal diameter of the collected material was 0.68 (±0.9) mm.

Conclusion: As expected, iLAAO can cause embolization of thrombotic material and other debris, either preexisting (e.g. embolization of echocardiographically undetected LAA thrombus) or induced by the procedure. This finding strongly encourages further investigations of the underlying mechanisms for embolization of different types of material, as well as the clinical impact of microemboli. Potential differences in thrombogenic potential between devices should also be addressed in future investigations. The potential for thrombo- embolism should be taken into account for device design and implantation techniques.

RATIONALE OF CEREBRAL PROTECTION DEVICES IN LEFT ATRIAL APPENDAGE OCCLUSION

Felix Meincke[1], Felix Kreidel[1], Tobias Spangenberg[1], Christian Frerker[1], Oscar Sanchez[2], Elena Ladich[2], Karl-Heinz Kuck[1], Alexander Ghanem[1]
[1] Asklepios Klinik St. Georg, Abteilung für Kardiologie, Hamburg, Germany
[2] CV Path Institute Inc., Gaithersburg, USA

Background: Periprocedural stroke has been reported after interventional left atrial appendage occlusion (iLAAO). In transcatheter aortic valve replacement (TAVR), the use of a cerebral protection device has been shown to reduce cerebral lesions assessed with magnetic resonance imaging. Our aim was to assess the feasibility of cerebral protection devices in iLAAO and to analyze the amount and type of debris captured.

Methods: In five consecutive patients undergoing iLAAO, the Senti-

nel CPS® cerebral protection device was used. For iLAAO, the Watchman® device was used in two patients and the Amulet® in three. After iLAAO, the filters underwent histopathological examination.

Results: A total of 10 filters (one proximal and one distal filter for each patient) were collected and underwent histopathological analysis (CV Path Institute Inc.). Debris was found in all patients (9/10 filters). Acute thrombus was found in 3 patients (2 Watchman®; 1 Amulet®), organizing thrombus in 4 patients (1 Watchman®; 3 Amulet®). Two Amulet® patients had endocardial or myocardial tissue in their filters. None of the filters included calcifications or other foreign material. The maximal diameter of the collected material was 0.68 (±0.9) mm.

Conclusion: As expected, iLAAO can cause embolization of thrombotic material and other debris, either preexisting (e.g. embolization of echocardiographically undetected LAA thrombus) or induced by the procedure. This finding strongly encourages further investigations of the underlying mechanisms for embolization of different types of material, as well as the clinical impact of microemboli. Potential differences in thrombogenic potential between devices should also be addressed in future investigations. The potential for thrombo- embolism should be taken into account for device design and implantation techniques.

ANTICOAGULATION MANAGEMENT AFTER LEFT ATRIAL APPENDAGE CLOSURE WITH THROMBUS FORMATION AND HIGH BLEEDING RISK

Dr. Inés Toranzo-Nieto[1], Dr. Victor Exposito[1], Dr. Felipe Rodriguez-Entem[1], Dr. Susana Gonzalez-Enriquez[1], Dr. Rocio Perez-Montes[2], Dr. Javier Ruano[3], Dr. Ignacio Garcia-Bolao[4], Dr. Juanjo Olalla[1]

[1] Hospital Universitario Marques de Valdecilla; Invasive Electrophysiology; Adult cardiology, Santander, Spain
[2] Hospital Universitario Marques de Valdecilla; Coagulation Disorders; Haematology, Santander, Spain
[3] Hospital Universitario Marques de Valdecilla; Echocardiography; Adult Cardiology, Santander, Spain
[4] Clinica Universitaria; Invasive Electrophysiology; Adult Cardiology, Pamplona, Spain

Background: Device associated thrombus formation is a feared complication of left atrial appendage closure (LAAO). Anti- coagulation management in this setting remains a challenge, as patients frequently suffered from comorbidities that increase bleeding risk.

History and Indication For Intervention: A 75- year-old male (82 kg) with persistent atrial fibrillation and past medical history of hypertension, dyslipidemia, chronic renal failure (creatinine clearance 25-30 ml/min, serum creatinine 2.2 mg/dL) and peripheral arterial disease (CHADS-VASc= 5) had to stop oral anticoagulation because of gastro-intestinal bleeding under acenocumarol and apixaban (2.5 mg bid). Gastroenterology studies were performed, showing duodenal angiodysplasia and gastric and sigma polyps. Several trials of electrocoagulation along with octreotide treatment were tried unsuccessfully. Patient experienced several bleeding episodes with secondary iron-deficiency anemia. He underwent several transfusion and treatment with endovenous iron and EPO.At the same time, echocardiogram showed severe left ventricular dysfunction (EF 25-30%) in the context of tachymyo- cardiopathy, despite optimization of antiarrhythmic and chronotropic drugs.

Due to these problems, oral anticoagulation was discontinued, and pulmonary vein ablation and percutaneous left atrial appendage closure were planned.

Intervention: Pulmonary vein isolation was conducted under general anesthesia, using a standard point-by-point ablation with irrigated catheter (Navistar Thermocool, Biosense Webster, CA, USA). LAAO was performed with Watchman device (Atritech, Inc, Plymouth, Minnesota, MN) implantation, immediately after the ablation procedure. The ablation catheter was removed and the initial sheath was replaced by a 14F transseptal access sheath (Atritech, Inc, Plymouth, MN), which was positioned in the LAA. The Watchman device access sheath and dilator was advanced over the wire into left atrium. Size and shape of the LAA was determined by using monoplane fluoroscopy (with pigtail catheter and additional angiograms, RAO 30o) and 3-dimensional TEE guidance. LAA ostium diameter varied between 19-23 mm in different angles (from 0o to 135o), and LAA depth was 26 mm. Under fluoroscopy guidance, delivery catheter was advanced into the access sheath until the most distal marker band, and deployed as per manufacturer's recommendations. Release criteria (position, anchor, size and seal) were met, and Watchman device (no 30) properly placed, stable during tug test, without any leak, and high compression.

A COMPARISON OF 2-D AND 3-D ECHOCARDIOGRAPHY IMAGING DURING PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE (LAAO)

Katarzyna Mitrega, Witold Streb, Magdalena Szymala, Tomasz Podolecki, Zbigniew Kalarus

Department of Cardiology, Congenital Heart Diseases, and Electrotherapy Medical University of Silesia, Silesian Center of Heart Diseases, Zabrze, Poland

Background: To chose an appropriate occluder size for left atrial appendage occlusion (LAAO), accurate assessment of the ostium and landing zone dimensions is essential. To date, the utility of 3-D versus 2-D has not been examined.

Objective: The aim of this study was to compare 2-D and 3–D echocardiography imaging performed during LAAO by two independent echocardiographers and to assess reproducibility of either method.

Methods: We analyzed 33 consecutive patients who underwent LAAO in our clinic. During LAAO the patients were anesthetized and the TEE was performed. Two independent echocardiographers measured LAA ostium and landing zone via 2-D and 3-D TEE.

Results: Mean values of ostial diameters measured in 2-D TEE by two independent echocardiographers were 23.8±4.4 vs 25.2±5.4 (P=0.04) and mean landing zone diameters were 18.3±4.4 vs 19.9±4.0 (P=0.005). In 3-D TEE mean ostial diameter was 29.5±5.3 vs 30.4±6.5 (P=0.07) and the landing zone 21.9±3.8 vs 22.2±3.9 (P=0.23). When the 2-D and 3-D measurements were compared, the ostial and landing zone diameters differed significantly (P<0.0001 and P<0.001 respectively).

Conclusions: There are significant differences between 2-D and 3-D TEE measurements of the ostial and landing zone diameters. 3-D measurements may be more reproducible than 2-D measurements.

LEFT ATRIAL APPENDAGE CLOSURE USING LEFT FEMORAL VEIN APPROACH

Naseer Ahmed[1,2,3], Giulio Molon[3], Guido Canali[3], Patrizio Mazzone[4], Natasja MS de Groot[2], Laura Lanzoni[3], Franscesco Onorati[1], Enrico Barbieri[3], Giuseppe Faggian[1]

[1] *Division of Cardiac Surgery, University of Verona Medical School, Verona, Italy*

[2] *Department of Cardiology, Erasmus Medical Center, Rotterdam, Netherlands*

[3] *Cardiology Department, Sacrocuore Hospital, Negrar, Verona, Italy*

[4] *Arrhythmology Department, S. Raffaele hospital, Milan, Italy*

Introduction: Atrial Fibrillation (AF) is the most common tachyarrhythmia and is associated with major complications such as thromboembolic events. Oral Anticoagulation (OAC) therapy remains an important component of AF treatment to avoid thrombo- embolism. Left Atrial Appendage (LAA) closure may be considered in patients with AF with high stroke risk and contraindications for long term OAC therapy. Devices for LAA closure are usually placed trans-septally using the Right Femoral Vein (RFV) approach (1; 2). Alternative approaches for accessing the left atrium have been reported, (2-6) but there are no reports on usage of the Left Femoral Vein (LFV) for LAA closure by using watchman device, that is unusual for septal puncture(7). In this report, we describe a LAA closure in an 83 year old patient using the LFV approach.

History and Physical Examination: An 83 year old male patient, with permanent AF with CHADS2 score 3, gastrointestinal bleeding (HAS-BLED = 5) was admitted at our hospital. The medical history included myocardial infarction, percutaneous coronary angio- plasty, dilated ischemic cardiomyopathy, moderate left ventricular dysfunction, NYHA class II, moderate renal failure and hypertension.

Imaging: On routine pre-procedural Echocardiogram, dilated cardiomyopathy and moderate ejection fraction dysfunction were observed. CT angiography done to observe vascular anatomy, demonstrated deployment of right common iliac vein towards left side (Fig 1 a,b). TransEsophageal Echocardiogram (TEE) used during procedure was very helpful to identify exact point (fossa ovalis) for puncture of interatrial septum(8) to approach LAA.

Indication For Intervention: The patient was considered a candidate for LAA closure using a Watchman device in order to avoid OAC therapy, according to current guidelines (9).

Intervention: Classically, the puncture site is reached by pulling the trans-septal sheath down into respectively the right atrium and Fossa Ovalis (FO) while observing the two drop movement. When using the LFV approach, this maneuver is very difficult and usually unsuccessful (10), particularly due to the angulation at the junction between the left common iliac vein and inferior vena cava. This angulation turns the needle away from the interatrial septum, thus hampering good contact with the wall of FO. In our case, we were unable to see the two drop movements into the right atrium and FO even when using needles with different curves. Then, we combined fluoroscopic and TEE images to confirm the exact position of the trans-septal sheath and subsequently steer it into the FO (Fig. 2 b, d). Using this approach we successfully performed puncture and implanted the Watchman device (Fig. 2 g).

Result: There were no complications and the patient was discharged on the third postoperative day. After two years of follow-up the patient remains asymptomatic, free of OAC therapy and without any cerebrovascular events.

Conclusion: In conclusion, trans-septal puncture guided by a combination of fluoroscopic and TEE images can be safely carried out using the LFV approach as an alternative option when the RFV is not accessible.

THORACOSCOPIC ATRICLIP CLOSURE OF LEFT ATRIAL APPENDAGE AFTER FAILED LIGATION VIA LARIAT

Primary author: *Christopher R. Ellis, MD, FACC, FHRS, Assistant Professor of Medicine, Director Cardiac Electrophysiology Laboratory, Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center*

Corresponding author: *Sam G. Aznaurov, M.D., Fellow-in-training, Clinical Cardiac Electrophysiology, Cardiovascular Medicine, Vanderbilt University Medical Center*

Additional authors: *Stephen K. Ball, M.D., Assistant Professor Cardiac Surgery, Vanderbilt University Medical Center*

Conflicts of Interest And Financial Disclosures:

Christopher R Ellis, MD, FACC, FHRS:

Received consulting fees/honoraria (<$10,000 per year) from Medtronic, Sentre Heart, AtriCure, Boston Scientific and Boehringer Ingelheim. Received significant research funding from Thoratec, HeartWare, Boston Scientific, Boehringer Ingelheim and Medtronic. Member of Scientific and Advisory Board: Sentre Heart, AtriCure.

Sam G. Aznaurov, MD: None Stephen K Ball, MD: None

Clinical History And Imaging: A 68-year-old male with paroxysmal AF was evaluated for ligation of the LAA via LARIAT sub-xiphoid approach. His CHA2DS2-VASc score was 4 for hypertension, prior cerebrovascular accident, and age >65 years. He was intolerant of anticoagulation with both dose-adjusted warfarin and rivaroxaban, due to recurrent, transfusion-dependent gastroin- testinal hemorrhage. His HAS-BLED score was 4. Pre-procedure gated CT angiography revealed an anteriorly directed LAA of chicken wing morphology, with a small secondary lobe near the ostium. He underwent LAA ligation utilizing a LARIAT ligature, via standard trans-septal and sub-xiphoid pericardial approach under general endotracheal anesthesia. The suture delivery device was cinched over the proximal neck of the LAA, and complete closure of the LAA ostium was initially noted (Figure 1a). However, after tightening the LARIAT, repeat contrast angiography of the LAA demonstrated gradual reopening of the LAA ostium and proximal lobe, as the delivery device was removed. A second LARIAT Plus ligature was used to re-snare the proximal neck of the LAA, but reopening of the LAA ostium was seen on repeat contrast angiography (Figure 1d). The patient was referred to the cardiothoracic surgery service for closure of the residual lobe of the LAA with an Atriclip-Pro device.

Intervention: Totally thoracoscopic access was obtained to the left chest under general endotracheal anesthesia. The pericardium was opened posteriorly to the phrenic nerve, and the LAA was visualized. The two previously deployed LARIAT ligatures were seen, and early ischemia of the LAA superior lobe was noted distal to the suture ligation neck (Figure 2). The basal accessory lobe of the

LAA remained unaffected by these ligatures. A 40mm Atriclip-Pro was

deployed at the base of the LAA, achieving complete occlusion. The patient tolerated the procedure well, and following an uneventful postoperative course he was discharged to home 3 days later. Followup gated cardiac CT angiography showed complete closure of the LAA by Atriclip-Pro.

Discussion and Learning Points: Device-assisted epicardial closure of the LAA is an evolving option for the prevention of systemic embolism in patients with AF. While this is a safe and effective therapy for patients who are intolerant of anticoagulation, there is limited experience with these devices, and operators need to be aware of the potential for both early and delayed complications. To our knowledge, this is the first reported case of the use of a thoracoscopically deployed Atriclip-Pro device to acutely salvage an incomplete LAA ligature by the LARIAT device.

During deployment, LAA anatomy was such that, even with incomplete closure of the LAA by both the LARIAT and the LARIAT Plus ligatures, the appendage appeared occluded by direct compression from the LARIAT suture delivery device. After the LARIAT delivery catheter was removed off the LAA base and angiography was again performed, a remaining trabeculated infundibulum was noted. In contrast to the smooth-walled residual "stump" which is sometimes seen following epicardial LAA exclusion, this remaining trabeculated portion of the LAA may serve as a potential cardioembolic source. Furthermore, early thrombosis at the site of LAA ligation has been well described following the LARIAT procedure, and is postulated to be the result of endothelial injury and inflammation producing a nidus for thrombus formation. Due to the residual risk of LAA thrombosis, the patient was referred to cardiac surgery service for completion of LAA exclusion.

Although totally thoracoscopic deployment of the Atriclip-Pro device is well described, its use in this scenario is novel. This case demonstrates the feasibility of completion of LAA closure following incomplete LAA ligation by sub-xiphoid approach. Additionally, this case highlights the possibility of incomplete LAA closure despite a favorable appearance on angiography during deployment of the LARIAT suture delivery device.



Figure 1. Intra-procedural fluoroscopy during initial deployment of the LARIAT over the neck of the LAA (a), with incomplete closure on post ligation angiogram (b). LARIAT Plus deployment, again over the neck of the LAA (c). Final angiographic appearance of the LAA, with the trabeculated secondary lobe unaffected by LARIAT Plus ligature (d).



Figure 2. Thoracoscopic appearance of the Atriclip device (AC, white), over the previously ligated left atrial appendage (LAA, blue) as well as the previously unaffected secondary lobe (LAA*, yellow). Previously deployed LARIAT ligatures are also seen (Lig, black).